TrialChinese journal of cancer2016

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Masahito Kotaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.